

Summary of Utilization Management (UM) Program Changes

November 2022

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
<i>Enbrel</i>	etanercept	<p>Enbrel will be moving to a preferred brand effective 1/1/2023. The Enbrel guideline has been updated for all indications to be a preferred product, thus not requiring a trial of another immunomodulator drug.</p> <p>Based on the FDA-approved indications, multiple other guidelines have been updated to include Enbrel as one of the preferred drugs, where the guidelines previously required a trial of one or more drugs before Enbrel would be approved.</p>	Update	1/1/2023
<i>Tysabri</i>	natalizumab	For the Crohn's disease indication, the trial and failure of one oral agent no longer includes aminosalicylates (least likely to be used for moderate to severely active disease) and the drug requires prescribing by or in consultation with a gastroenterologist.	Update	1/1/2023